Seventeen children with advanced myeloid malignancies (induction failure, relapse, myelodysplasia, secondary AML, or CR Ͼ1) received thiotepa 750 mg/m 2 i.v., busulfan 12 mg/kg or 640 mg/m 2 p.o., and cyclophosphamide 120 mg/kg i.v. as a preparative regimen for allogeneic or autologous hematopoietic stem cell (HSC) transplantation. Of the 15 allogeneic transplants, eight were from matched siblings, one was from a mismatched sibling, and six were from unrelated donors. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine or tacrolimus and methotrexate. Regimen-related toxicity was common but tolerable, affecting mainly the skin and gastrointestinal tract. Three patients died early and were not evaluable for engraftment; engraftment occurred in the remaining patients. Nine patients with active disease at the time of transplant were evaluable for response; all achieved remission. With a median follow-up of 40 months (range, 10-71 months), nine patients are alive and disease-free. The 3-year actuarial event-free survival was 51% (95% confidence interval (CI) 27-76%). Seven patients died of transplant-related complications: infection (n = 4), chronic GVHD (n = 1), veno-occlusive disease, VOD, (n = 1) and pulmonary alveolar hemorrhage (n = 1). Only one patient had leukemia relapse and died. We conclude that the use of high-dose thiotepa, busulfan and cyclophosphamide is an effective conditioning regimen for childhood myeloid malignancies and may be tested in patients with less advanced disease (eg CR1).
transplants in these patients is primarily caused by a higher relapse rate, although greater treatment-related mortality (TRM) is also encountered. These patients often do not have a matched sibling donor, and the use of alternative donors is necessary. Transplantation using such donors may provide a greater graft-versus-leukemia effect but is often associated with a higher incidence of complications, although, outcomes of matched-sibling or unrelated donor BMT in patients with high-risk leukemia appeared equally poor. 8, 9 Reports of BMT with high-risk myeloid malignancies include mostly adult patients; data concerning transplant outcomes in children are limited. In several series of marrow transplants in children, patients with high-risk myeloid malignancies had 2-year disease-free survival rates of 32-35%. [10] [11] [12] The results were not affected by T lymphocyte depletion of the graft.
Transplant preparative regimens have included high-dose chemotherapy with or without total body irradiation (TBI). Comparative studies of regimens with and without TBI have shown equal efficacy in BMT outcome among AML patients in first complete remission. 13, 14 Because of the known side-effects associated with TBI, a chemotherapyonly regimen is preferred for children. The combination of busulfan (BU) and cyclophosphamide (CY) is an effective preparative regimen in early stage AML but fails to prevent relapse in patients with advanced disease. Other high-dose chemotherapy protocols have not been found to be superior, 5, 15, 16 and none has been evaluated exclusively in pediatric patients.
The alkylating agent thiotepa possesses antileukemic activity in vitro and may be enhancing engraftment through immunosuppressive properties. 17 Its dosage can be escalated more than 15 times with HSC support. There are no significant overlapping dose-limiting toxicities between thiotepa and BU or CY. We previously reported on the use of the combination of thiotepa, BU and CY for the conditioning of adults with hematological malignancies. 18 Here, we review the use of this regimen for transplantation in children with high-risk myeloid malignancies.
Materials and methods

Patients
From September 1992 to October 1997, 17 children with high-risk myeloid malignancies (defined as AML beyond CR1, refractory disease, or myelodysplasia with unfavor-able cytogenetics) received high-dose thiotepa, BU and CY as conditioning before hematological stem cell transplantation. Patient characteristics are listed in Table 1 . Eligibility criteria included age Ͻ19 years, Lansky performance status Ͼ70%, no active CNS disease, left ventricular ejection fraction Ͼ50%, normal pulmonary function tests with diffusion capacity Ͼ50% of predicted value, serum creatinine Ͻ1.5 mg%, serum bilirubin Ͻ2 × upper limits of normal, SGPT Ͻ3 × upper limits of normal, no active infection, and no concomitant life-threatening illness. All patients were HIV seronegative. The study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board, and written informed consent was obtained from all patients and/or guardians.
Preparative regimen
The first six patients received a preparative regimen consisted of thiotepa 250 mg/m 2 i.v. on days −9, −8, −7; BU 1 mg/kg orally every 6 h for 12 doses on days −6, −5, and −4; and CY 60 mg/kg i.v. on days −3 and −2. HSC was infused on day 0. The next 11 patients treated were enrolled on a busulfan pharmacokinetic study. The dose and schedule of thiotepa and cyclophosphamide were identical, and patients received the first dose of BU at 40 mg/m 2 orally. Subsequent doses were adjusted based on the initial dose pharmacokinetics with a targeted area under the curve (AUC) of 1000-1500 mol × min/l.
Thiotepa was given i.v. once daily as a 4-h infusion. To remove drug excreted in the sweat, patients were required to shower thoroughly twice (four times in the last six patients) daily on the days thiotepa was administered through 24 h after the last thiotepa dose. All patients received an anticonvulsant from 24 h before the first dose of BU to 24 h after the last dose. The first five patients received phenytoin 10 mg/kg/day orally, and the last 12 were given clonazepam 0.05 mg/kg every 6 h i.v. CY was given once daily as a 2-h infusion. Mesna was administered 
Hematopoietic stem cell collection
Bone marrow was harvested and processed by standard procedures (n = 11). Blood stem cells were collected from filgrastim-treated donors (n = 5) by apheresis until a minimum of 4 × 10 6 CD34 + cells/kg recipient body weight were collected. 19 No T cell depletion was performed. Two patients received autologous HSC transplants in CR2: one from bone marrow harvested during second remission and the other with autologous blood stem cells collected during first remission. Neither specimen was purged to remove residual leukemic cells. The unrelated umbilical cord blood unit was obtained from the New York Blood Center. It was serologically mismatched with the patient at one HLA class II locus, with a total nucleated cell dose of 2.5 × 10 7 /kg recipient body weight.
GVHD prophylaxis and treatment
The first five patients of the series received CsA plus MTX and the last 10 received tacrolimus plus MTX for GVHD prophylaxis. The five patients receiving cyclosporin A (CsA) were given 3 mg/kg/day i.v. continuous infusion from day −2, and doses were adjusted to maintain whole blood steady state or trough levels at 250-350 ng/ml by RIA for parent drug. They also received MTX at 15 mg/m 2 i.v. on day 1 and 10 mg/m 2 i.v. on days 3, 6 and 11. The last 10 allogeneic transplant recipients received FK506 at 0.03 mg/kg/day i.v. by continuous infusion from day −2, and doses were adjusted to maintain whole blood steady or trough levels at 5-15 ng/ml by immunoassay. They also received MTX 5 mg/m 2 i.v. on days 1, 3 and 6 for related donors and also on day 11 for unrelated or blood stem cell donors. Following engraftment, when the patient was able to eat, CsA or FK506 was converted to oral administration to day 180 and tapered thereafter. Patients who developed grade 2 GVHD were treated initially with methylprednisolone at 0.5 mg/kg i.v. every 6 h. Antithymocyte globulin 10 mg/kg/day was given to patients with steroidrefractory GVHD.
Supportive care
Filgrastim 5 g/kg/day was given subcutaneously from day 7 for patients receiving a marrow graft and from day 1 for patients receiving other HSC grafts. It was continued until the neutrophil count exceeded 1.5 × 10 9 /l for 3 days. All blood products were irradiated and filtered. Red blood cell and platelet transfusions were given to maintain a hemoglobin of Ͼ80 g/l and platelet count Ͼ20 × 10 9 /l. Infection prophylaxis during the peritransplant period consisted of acyclovir 5 mg/kg i.v. every 8 h. All patients received broad-spectrum antibiotics for neutropenic fever and hyperalimentation when needed. Intravenous immunoglobulin 200-500 mg/kg was given weekly to day 100, and monthly thereafter to 1 year. When engraftment had occurred, the patients received twice-weekly trimethoprim-sulfamethox-azole or weekly dapsone orally, and CMV-seropositive patients received prophylactic ganciclovir to day 100.
Toxicity grading
Regimen-related toxicity (RRT) was graded as described 20 except that death after day 28 resulting from RRT was also scored as grade 4. The maximum toxicity was the highest score recorded in any individual organ system. Adverse events that can clearly be attributed to culture-documented infection, bleeding, other medications, or GVHD were not scored as RRT.
Assessment of engraftment, response and GVHD
Myeloid engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count у0.5 × 10 9 /l, and platelet recovery was defined as the day the platelet count was у20 × 10 9 /l with no platelet transfusions the following week. Patients who died within the first 14 days after transplantation are not included in the evaluation of graft failure. Bone marrow aspirates were examined for morphology and chimerism at 1, 3, 6, 12, 18 and 24 months after transplant. A complete remission was defined as a neutrophil count Ͼ0.5 × 10 9 /l, no blasts in the peripheral blood, and Ͻ5% blasts in the bone marrow. Hematopoietic chimerism was evaluated by conventional cytogenetics for sexmismatched patient-donor pairs and by DNA restriction fragment length polymorphisms at the AY-29 or YNH24 locus as described previously. 21 Diagnosis of GVHD was based on clinical and histological data. GVHD was graded according to the consensus criteria. 22 Patients who died prior to myeloid engraftment were not evaluable for GVHD.
Statistical analysis
All patients were followed to 1 August 1998. At the time of analysis, median time from transplantation was 40 months (range 10-71 months) for all subjects. Actuarial estimates of time to engraftment, acute GVHD, relapse, death, and treatment-related mortality (non-relapse death) were calculated according to the method of Kaplan and Meier.
Results
Patient characteristics
Seventeen patients were treated, and all were at high risk for recurrence of disease (Table 1) . At the time of transplant, 12 had active disease: induction failure (n = 2), refractory relapse (n = 7), and myelodysplasia (n = 3). The percentages of marrow blast cell in the 12 patients with active disease at the time of transplant ranged from 8.5 to 92% (median 36%). The patients with myelodysplasia had refractory anemia with excessive blasts (n = 2), and refractory anemia with ringed sideroblasts (n = 1). The cytogenetic abnormalities of these three patients included trisomy 8, monosomy 7, and therapy-related multiple aberrations. Five patients were in remission at the time of transplant: first (epipodophyllotoxin-related secondary AML, n = 1), second (n = 2), third (n = 1), fourth (n = 1). Nine patients, who had a first remission, had a median duration of 9 months (range 3-20 months). HSC were obtained from bone marrow (n = 11), peripheral blood (n = 5) and umbilical cord blood (n = 1).
Eleven of these patients were on the pharmacokinetic study. 23 On the basis of the initial AUC of the first oral dose of BU, seven patients required their subsequent doses adjusted to the targeted range of 1000 to 1500 mol × min/l. The median total dose of BU administered for these 11 patients was 456 mg/m 2 . The remaining six patients did not have pharmacokinetic analysis of their busulfan dosages.
Hematopoietic recovery and chimerism
Three patients died on days 6, 10 and 14 and could not be evaluated for engraftment. Of the remaining 14 patients, all had engraftment documented by laboratory, cytogenetic and/or molecular criteria. The median time to a granulocyte count of Ͼ0.5 × 10 9 /l was 14 days (range 12-33 days); the median time to attain a platelet count of Ͼ20 × 10 9 /l was 26 days (range 18-178 days). No significant differences were noted between patients receiving bone marrow or pheresis HSC. All patients had complete chimeric states documented at 6, 12, 18 and 24 months.
Early regimen-related toxicity (Table 2)
Some degree of RRT occurred in 88% of the patients. The incidence of grade 3-4 RRT in individual organ systems varied from 0% to 6%. The oral cavity and the gastrointestinal tract were common sites of toxicity, but no patient developed grade 3-4 RRT in either system. Because of severe esophagitis and diarrhea, all but two patients received parenteral nutritional support. Hepatic toxicity was common but reversible. In some cases it was difficult to determine if other concurrent conditions (such as GVHD or sepsis) may have aggravated the liver abnormalities. Only two patients developed VOD, which in one was fatal.
Although cutaneous toxicity is not formally included in the grading system, essentially all patients developed intertriginous hyperpigmentation, and about a third progressed to moist desquamation requiring local care. No patient developed life-threatening or fatal skin toxicity. The sever- Table 2 Individual organ toxicity ity of cutaneous changes was reduced when patients were instructed to shower four times daily during the days of thiotepa administration.
Acute and chronic GVHD
Three patients died before engraftment and were not evaluable for acute GVHD. The actuarial incidence of grade II-IV acute GVHD in the remaining 12 patients was 87% (CI 65-100%). There was no significant difference in the grade of GVHD among the patients receiving unrelated or matched donor HSC (Table 3 ). Of the nine allogeneic patients surviving beyond day 100, five developed chronic GVHD. One of them died of respiratory failure secondary to bronchiolitis obliterans 2 years after the transplant. Two other patients remain on treatment at the time of this report, with Lansky performance scores of 70 and 100%, respectively.
Response and survival
Twelve of the 17 patients had measurable disease at the time of transplant; three died too early to be evaluable for response. The remaining nine patients achieved complete remission when evaluated at 1 month post-transplant. Seven patients died of non-relapse causes, which included infection (n = 4), VOD (n = 1), pulmonary alveolar hemorrhage (n = 1), and chronic GVHD (n = 1). The 3-year TRM rate was 43% (19-68%). One patient died of recurrent leukemia 7 months after complete remission following transplant. The 3-year relapse rate was 9% (0-26%). Currently, nine patients are alive in continuous complete remission 10 to 71 months (median 40 months) after transplant. The 3-year actuarial disease-free survival (DFS) rate was 51% (CI 27-76%) (Figure 1 ). Both patients with autologous HSC transplant are alive. Four of the five patients transplanted in remission are alive and disease-free, while five of the 12 patients transplanted with active disease are alive and disease-free.
Discussion
In this study, a standard preparative regimen of BU and CY was intensified by the addition of a third alkylating agent, thiotepa, and used for transplantation in children with advanced myeloid malignancies. A previous phase I-II study 18 in adults established the maximal tolerated dose schedule, which was applied in the current protocol. Grade 1-4 RRT occurred in 88% of patients, but we identified a grade 3-4 RRT rate of 12%, which compares favorably with the 27% incidence of severe or fatal RRT reported in our adult population treated at the same dosage level. 24 Severe RRT with the standard BU/CY preparative regimen is rare in children with AML who receive transplants during first remission, 14, 25 but there is little comparable information for those with high-risk myeloid disease. Hepatic toxicity with clinical manifestations consistent with VOD was the most common grade 3-4 RRT encountered in our adult patients who received transplants on this regimen. 18, 24 One of our pediatric patients died of VOD before the institution of the BU pharmacokinetic study. None of the 11 patients on the pharmacokinetic trial had evidence of VOD, suggesting that the adjusted dose approach may help reduce this complication in a heavily pretreated patient population.
The actuarial day-180 non-relapse mortality in our patients was 38%. Considering the high-risk nature of the disease in these patients, the inclusion of alternative donors, and the poor performance status at the time of transplantation, this figure is comparable with that reported in other series. 2, [8] [9] [10] 12, 26, 27 The majority of deaths in this series resulted from infection, which is common in patients with active leukemia undergoing BMT. In adult patients, the short-term outcome of allogeneic transplantation has been improved with blood stem cell grafts. 28 We are evaluating a similar approach in children who have an HLA-identical sibling donor.
Six patients received HSC transplant from unrelated donors and engraftment occurred in all these patients, even though TBI and additional immunosuppression were not included in the protocol. Thiotepa has been shown to enhance durable engraftment in genetically disparate grafts and appeared to be effective in our patients. 29 If proven in a larger series, this combination will be attractive for use in children because it avoids the late side-effects of TBI.
Despite the fact that many of our patients had extensive prior therapy and/or were resistant to conventional treatment, all patients with active disease achieved CR. The relapse rate has been low. While one can argue that this low relapse rate does not take into account possible relapses in the patients who died from TRM, the duration of followup has been fairly long, with all patients having a followup exceeding 10 months at the time of reporting. The outcome of BMT is affected by the duration of the first remission; patients who relapse within 1 year of initial diagnosis have a poorer DFS.
1,2 Only four of our AML patients had an initial remission of greater than 1 year. The overall 2-year actuarial event-free survival rate of 51% compared favorably with that of other studies of high-risk patient populations. For example, Wells et al 1 reported a 47% 2-year DFS in children who received transplants in CR2. Sanders 7 observed a 35% DFS at 8 years for 13 pediatric patients with AML who received transplants beyond first remission. Three of our nine patients with refractory leukemia survived disease-free, a phenomenon rarely seen in other series. 30 However, because of the small number of patients treated, the heterogeneity of their clinical conditions and types of transplant performed, a definitive conclusion about the efficacy of this regimen cannot be made. We feel that this combination deserves further evaluation in a more homogeneous population of children with highrisk myeloid malignancies, preferably in remission and with a good performance status.
